<DOC>
	<DOCNO>NCT00630864</DOCNO>
	<brief_summary>This open-label , multicenter , international study design determine TTR stabilization well Fx-1006A safety tolerability , effect clinical outcome patient non-V30M TTR amyloidosis . Strong pre-clinical clinical evidence support daily dose 20 mg Fx-1006A optimum dose achieve stabilization tetrameric TTR ATTR-PN patient . Since disease presentation similar V30M non-V30M TTR mutation associate ATTR-PN Fx-1006A show stabilize wild-type V30M TTR vitro ex vivo , present study conduct determine effect Fx-1006A TTR stabilization ATTR-PN patient TTR mutation V30M . Safety exploratory efficacy Fx-1006A administer daily 12 month also evaluate patient population . This open-label , multicenter , international study design determine TTR stabilization well Fx-1006A safety tolerability , effect clinical outcome patient non-V30M TTR amyloidosis . The study conduct two part . Part 1 include six-week dosing period enrol patient receive oral Fx-1006A 20 mg soft gelatin capsule daily six week . At Week 6 , blood sample collect patient determine TTR stabilization . Patients complete Week 6 visit continue receive daily oral Fx-1006A 20 mg total 12 month Part 2 study . If determine patient stabilize Week 6 , patient discontinue study . During Part 2 , clinical outcome measure Months 6 12 , base NIS , Norfolk QOL-DN , mBMI , NCS , HRDB , SF-36 , Karnofsky score , echocardiography ; NT-pro-BNP troponin I level measure Baseline , Weeks 2 6 , Months 3 , 6 , 12 . Pharmacokinetic measurement make use sample collect Baseline , Week 6 , Months 6 12 . Safety tolerability assess throughout study base vital sign , physical examination , ECG , echocardiography , 24-hour Holter monitoring , clinical laboratory test ( hematology , serum chemistry , urinalysis ) , monitor adverse event concomitant medication use . Day 1 define administration first dose study drug . Clinic Visits conduct Screening ( Days -30 -1 ) Baseline ( Day 0 ) , Week 2 , Week 6 , Months 3 , 6 , 12 ( ± 2 week schedule date post-Baseline visit ) . Monthly telephone contact ( + 1 week schedule date ) make month investigative site visit schedule ( Months 4 , 5 , 7 , 8 , 9 , 10 , 11 ) assessment adverse event concomitant medication . A final telephone contact assess adverse event concomitant medication usage make 30 day last dose study drug . Patients discontinue study time follow enrollment final visit perform , include safety assessment , time discontinuation . Any patient discontinue Month 6 visit also exploratory assessment perform .</brief_summary>
	<brief_title>The Effects Fx-1006A Transthyretin Stabilization Clinical Outcome Measures Patients With Non-V30M Transthyretin Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Amyloid Neuropathies , Familial</mesh_term>
	<criteria>Patient amyloid document biopsy ( accordance institutional site standard care ) . Patient documentation one following target TTR mutation : Ser77Tyr , Thr60Ala , Tyr114Cys , Leu58His , Glu89Gln , Ser77Phe , Thr49Ala , Ile107Val , Val30Ala , Gly47Ala , Gly47Glu , Leu55Arg , Lys70Asn , Ile84Thr , Ile107Met . Patients mutation list may enrol approval Sponsor . Patient peripheral and/or autonomic neuropathy and/or cardiomyopathy Karnofsky Performance Status ≥ 50 . Patient age ≥18 75 year , inclusive . If female , patient postmenopausal , surgically sterilize , willing use two acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide ) throughout study 3 month end study . ( A condom alone consider acceptable method birth control . ) If male female partner childbearing potential , willing use two acceptable method birth control duration study . For female male , acceptable birth control must use least 3 month last dose study medication . Patient , opinion investigator , willing able comply study medication regimen study requirement . Chronic use nonsteroidal antiinflammatory drug ( NSAIDs ) , define great 34 times/month ( ibuprofen nimesulide permit ) . Patient primary secondary amyloidosis . Patient TTRassociated amyloidosis V30M mutation . If female , patient pregnant breast feeding . Patient receive prior liver transplantation . Patient expect undergo liver transplantation within 12 month enrollment . Patient positive result hepatitis B surface antigen ( HBsAg ) , antihepatitis C virus ( HCV ) , and/or human immunodeficiency virus ( HIV ) . Patient renal insufficiency ( creatinine clearance &lt; 30 ml/min ) . Patient liver function test abnormality : alanine transaminase ( ALT ) and/or aspartate transaminase ( AST ) &gt; 2 time upper limit normal ( ULN ) medical judgment investigator due reduce liver function active liver disease . Patient New York Heart Association ( NYHA ) Functional Classification ≥ III . Patient cause sensorimotor neuropathy ( B12 deficiency , Diabetes Mellitus , HIV treat retroviral medication , thyroid disorder , alcohol abuse , chronic inflammatory disease ) . Patient prior nonamyloid cardiac disease : myocardial infarction due obstructive coronary artery disease , active nonamyloid cardiomyopathy ( e.g. , symptomatic leave ventricular dysfunction cause amyloid , patient primary diagnosis symptomatic valvular heart disease ) Patient comorbidity anticipate limit survival le 12 month . Patient receive investigational drug/device and/or participate another clinical investigational study within 60 day Baseline ( Day 0 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Transthyretin , TTR , amyloidosis , TTR amyloidosis , polyneuropathy</keyword>
</DOC>